natgillin/translations-raw huggingface dataset:
Mumps vaccine efficacy has also been suggested to be lower in high-transmission settings (Brockhoff 2004).
Kaže tudi, da je učinkovitost cepiva proti mumpsu manjša v okolju, kjer je možnost okužbe velika (Brockhoff 2004).
However foetal damage has not been documented when measles, mumps and rubella vaccines have been given to women who were unknowingly in early stages of pregnancy”.
Vendar pa škodljivih učinkov za plod pri dajanju cepiv proti ošpicam, mumpsu in rdečkam ženskam, ki niso vedele, da so v zgodnji fazi nosečnosti, niso dokumentirali“.
The CHMP recommended reordering of some of the statements and adding subtitles to clearly distinguish each precaution (i.e. thrombocytopenia, immunocompromised patients, and transmission).
CHMP je priporočil spremembo vrstnega reda nekaterih navedb in dodatne podnaslove za jasnejšo razmejitev previdnostnih ukrepov (tj. trombocitopenija, imunokompromitirani bolniki in prenos).
The CHMP was of the opinion that the statement on subjects with humoral and cellular deficiency was appropriate and in line with the approved contraindication of other MMR vaccines.
CHMP je bil mnenja, da je navedba o osebah s humoralno ali celično imunsko pomanjkljivostjo primerna in v skladu z odobreno kontraindikacijo za druga cepiva MMR.
The purpose of this Art 30 referral is to harmonise the SmPC across EU member states for Priorix and associated names.
Napotitev v skladu s členom 30 je namenjena uskladitvi povzetkov glavnih značilnosti zdravila Priorix in povezanih imen v državah članicah EU.
The CHMP noted that there are no theoretical risks of vaccination during breastfeeding.
CHMP je ugotovil, da s cepljenjem med dojenjem ni povezano teoretično tveganje.
However, since new and very complex childhood vaccines are under development it was recommended to list vaccines applicable for co-administration rather than to give a general statement on co-administration with other vaccines.
Vendar pa so v razvoju nova, zelo kompleksna cepiva za otroke, zato se priporoča navedba vseh cepiv, ki jih je mogoče uporabiti sočasno, ne pa splošna navedba o sočasni uporabi drugih cepiv.
In conclusion, the CHMP was of the opinion that the statement of “pregnancy” as a contraindication was in line with the approved contraindication of other MMR vaccines.
Zato je CHMP menil, da je navedba „nosečnosti“ kot kontraindikacije v skladu z odobreno kontraindikacijo za druga cepiva MMR.
For patients with thrombocytopenia or any coagulation disorder subcutaneous administration is recommended and thus a statement has been included.
Za bolnike s trombocitopenijo ali motnjo koagulacije se priporoča subkutano dajanje, kar je bilo prav tako vključeno v besedilo.
Systematic reviews on the safety, immunogenicity and efficacy of measles vaccination in children infected with HIV revealed that attenuated measles vaccine virus can caused severe complications or fatal disease in severely immunosuppressed HIV-infected patients.
Sistematski pregledi varnosti, imunogenosti in učinkovitosti cepiva proti ošpicam pri otrocih, okuženih z virusom HIV, so pokazali, da lahko oslabljen virus cepiva proti ošpicam povzroči hude zaplete ali smrtno bolezen pri bolnikih, okuženih z virusom HIV, ki imajo zelo oslabljen imunski sistem.
The MAH was however asked to consider restructuring section 4.8 in accordance with the SmPC guideline to provide clear and readily accessible information (summary of the safety profile, tabulated list of adverse reactions, description of selected adverse reactions).
Vendar je bil imetnik dovoljenja za promet z zdravilom naprošen, da razmisli o preoblikovanju poglavja 4.8 v skladu s smernicami za povzetek glavnih značilnosti zdravila, z namenom izboljšati jasnost in dostopnost informacij (povzetek varnostnega profila, seznam neželenih učinkov v obliki preglednice, opis izbranih neželenih učinkov).
The WHO classification of HIV-related disease in adults and children published in 2006 states the following: “Immunological criteria for diagnosing advanced HIV in a child younger than five years of age with severe HIV infection: %CD4+ <25 among those younger than 12 months %CD4+ <20 among those aged 12-35 months %CD4+ <15 among those aged 36-59 months”
V svoji razvrstitvi bolezni, povezanih z virusom HIV, pri odraslih in otrocih, objavljeni leta 2006, SZO navaja naslednje: „Imunološki kriteriji za diagnosticiranje napredovale okužbe z virusom HIV pri otrocih, mlajših od pet let, s hudo okužbo z virusom HIV: % CD4+ < 25 med otrocii, mlajšimi od 12 mesecev % CD4+ < 20 med otroci, starimi od 12 do 35 mesecev % CD4+ < 15 med otroci, starimi od 36 do 59 mesecev“ Obstajajo tudi poročila o ošpičnem encefalitisu z inkluzijskimi telesci po cepljenju MMR pri otrocih s primarno imunodeficienco in disgamaglobulinemijo (glejte Bitnun et al. 1999 Clin.
More recently Priorix has been coadministered with Haemophilus influenzae type b (Hib) and meningococcal C conjugate vaccines as well as with concomitant co-administration with hepatitis A inactivated vaccine and pneumoccocal 7-valent conjugate vaccine.
Nedavno so cepivo Priorix uporabili sočasno s cepivom proti Haemophilusu influenzae tipa b (Hib) in konjugiranim cepivom proti meningokokom ter sočasno in hkrati z inaktiviranim cepivom proti hepatitisu A in konjugiranim 7-valentnim cepivom proti pnevmokokom.
Section 4.5 - Interactions with other medicinal products and other forms of interaction Clinical studies demonstrated that Priorix can be administered concomitantly with live attenuated varicella vaccine, DTPa-IPV and combined hepatitis A/B vaccine (Marshall et al., 2006; Stuck et al., 2002; Usonis et al., 2005; Wellington and Goa, 2003).
Poglavje 4.5 - Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Klinične študije so pokazale, da se lahko cepivo Priorix daje sočasno s cepivom proti noricam, ki vsebuje živ oslabljen virus, DTPa-IPV in kombiniranim cepivom proti hepatitisu A/B (Marshall et al., 2006; Stuck et al., 2002; Usonis et al., 2005; Wellington and Goa, 2003).
The final agreed wording is: “PRIORIX can be given simultaneously (but at separate injection sites) with any of the following monovalent or combination vaccines [including hexavalent vaccines (DTPa-HBV-IPV/Hib)]: diphtheria-tetanus-acellular pertussis vaccine (DTPa), Haemophilus influenzae type b vaccine (Hib), inactivated polio vaccine (IPV), hepatitis B vaccine (HBV), hepatitis A vaccine (HAV), Meningococcal serotype C conjugated vaccine (MenC), varicella zoster vaccine (VZV), oral polio vaccine (OPV) and 10-valent pneumococcal conjugate vaccine in accordance with local recommendations.
Dogovorjeno je bilo naslednje končno besedilo: „Cepivo PRIORIX se lahko daje sočasno (vendar na različna mesta injiciranja) s katerim koli od naslednjim monovalentnih ali kombiniranih cepiv [vključno s heksavalentnimi cepivi (DTPa-HBVIPV/Hib)]: cepivom proti davici, tetanusu in brezcelično cepivo proti oslovskemu kašlju (DTPa), cepivom proti Haemophilus influenzae tipa b (Hib), inaktiviranim cepivom proti otroški ohromelosti (IPV), cepivom proti hepatitisu B (HBV), cepivom proti hepatitisu A (HAV), konjugiranim cepivom proti meningokokom serološke skupine C (MenC), cepivom proti virusu herpesa zostra (VZV), peroralnim cepivom proti otroški ohromelosti (OPV) in 10-valentnim konjugiranim cepivom proti pnevmokokom v skladu z lokalnimi priporočili.
Priorix is a combined freeze-dried measles (M), mumps (M), and rubella (R) vaccine (live) preparation.
Cepivo Priorix je kombinirano (živo) cepivo proti ošpicam (M), mumpsu (M) in rdečkam (R), sušeno z zamrzovanjem.
The risk for measles vaccination (enhancement of spontaneous abortion of stillbirth) is indicated to be unknown.
Navedeno je, da je tveganje, povezano s cepljenjem proti ošpicam (spontani splav ali mrtvorojenost), neznano .
So, there were no Priorix-specific data on mumps effectiveness and the general comments proposed by the MAH were endorsed by the CHMP.
Podatkov o učinkovitosti proti mumpsu, specifičnih za cepivo Priorix, torej ni bilo, zato je odbor CHMP odobril splošne opombe, ki jih je predlagal imetnik dovoljenja za promet z zdravilom.
According to the SmPC guideline, the text should not include reference to other medicinal products, so the MAH proposed to delete reference on the result of comparative studies that were present in the SmPC of some MSs.
V skladu s smernicami za povzetek glavnih značilnosti zdravila besedilo ne sme vključevati sklicev na druga zdravila, zato je imetnik dovoljenja za promet z zdravilom predlagal, da se sklic na rezultate primerjalnih študij, prisoten v povzetkih glavnih značilnosti zdravila nekaterih držav članic, briše.
These patients should be vaccinated with caution and preferably using subcutaneous route”.
Pri cepljenju teh bolnikov je potrebna previdnost, priporoča pa se subkutani način cepljenja“.
Review of pharmacovigiliance and published data does not indicate a risk of CRS in inadvertently vaccinated women, who are pregnant or conceived shortly after vaccination with Priorix.
Pregled farmakovigilančnih podatkov in objavljenih podatkov ne kaže na tveganje KSR pri nenamerno cepljenih ženskah, ki so noseče ali zanosijo kmalu po cepljenju s cepivom Priorix.
The data set provided by the MAH was generated by post-marketing data from the MAH's safety database and data from recent published literature about MMR vaccination in pregnant women.
Niz podatkov, ki jih je imetnik dovoljenja za promet z zdravilom predložil, je nastal iz podatkov v obdobju trženja cepiva iz zbirke podatkov o varnosti zdravila, ki jo vodi imetnik dovoljenja za promet, in iz novejših objavljenih podatkov iz literature o cepljenju nosečnic s cepivom MMR.
The MAH amended the corresponding part accordingly and also added another sentence to reflect the documented transplacental transmission.
Imetnik dovoljenja za promet z zdravilom je zadevni del ustrezno spremenil in dodal še en stavek o dokumentiranem prenosu prek placente.
The final agreed wording is: “Immunocompromised patients who have no contraindication for this vaccination (see section 4.3) may not respond as well as immunocompetent patients, therefore some of these patients may acquire measles, mumps or rubella in case of contact, despite appropriate vaccine administration.
Dogovorjeno je bilo naslednje končno besedilo: „Imunokompromitirani bolniki, pri katerih ni kontraindikacije za to cepivo (glejte poglavje 4.3), se morda ne bodo odzvali tako dobro kot imunokompetentni bolniki, zato se lahko kljub ustreznemu cepljenju ti bolniki ob stiku nalezejo ošpic, mumpsa ali rdečk.
The MAH implemented all comments made by the CHMP and the final agreed wording was: “There is limited experience with PRIORIX during breast-feeding.
Imetnik dovoljenja za promet z zdravilom je vse opombe odbora CHMP upošteval in dogovorjeno je bilo končno besedilo: „Izkušnje z uporabo cepiva PRIORIX med dojenjem so omejene.
Pharyngeal excretion of the rubella and measles virus is known to occur about 7 to 28 days after vaccination with peak excretion around the 11th day.
Znano je, da se virusa rdečk in ošpic iz grla izločata približno 7 do 28 dni po cepljenju, pri čemer je izločanje največje okoli 11. dneva.
In HIV infected children with no evidence of immunosuppression measles vaccine has been safe and the risk of vaccine induced virus disease is very low.
Pri otrocih, okuženih z virusom HIV, ki niso kazali znakov imunosupresije, je bila uporaba cepiva proti ošpicam varna, tveganje za virusno obolenje, sproženo s cepivom, pa zelo majhno.
In patients with existing thrombocytopenia or a history of thrombocytopenia after measles, mumps or rubella vaccination the risk-benefit of administering PRIORIX should be carefully evaluated.
Pri bolnikih z obstoječo trombocitopenijo ali trombocitopenijo v anamnezi po cepljenju proti ošpicam, mumpsu ali rdečkam je treba razmerje med koristmi in tveganji uporabe cepiva PRIORIX skrbno oceniti.
The major divergence in the approved SmPCs relates to the administration of Priorix in HIVinfected subjects.
Največje razhajanje v odobrenih povzetkih glavnih značilnosti zdravila se nanaša na uporabo cepiva Priorix pri osebah, okuženih z virusom HIV.
The data from spontaneous reports and the pregnancy registry have not indicated a safety concern with respect to spontaneous abortion or congenital malformations related to the inadvertent administration of Priorix in pregnant women.
Podatki iz spontanih poročil in registra nosečnosti ne kažejo na varnostno tveganje za pojav spontanih splavov ali prirojenih malformacij, povezanih z nenamerno uporabo cepiva Priorix pri nosečnicah.
The attenuated virus strain in the current rubella vaccine can rarely infect the foetus and there is no evidence that foetal infection with the vaccine virus is harmful.
Oslabljeni sev virusa v obstoječem cepivu proti rdečkam le redko okuži plod, dokazov o škodljivem vplivu okužbe plodu z virusom cepiva pa ni.
The MAH performed all the above changes but in order to be consistent with the SmPCs of all GSK vaccines the MAH asked to continue presenting adverse reactions as a list keeping a separation between the adverse reactions reported in clinical trials and the adverse reaction reported in postmarketing.
Imetnik dovoljenja za promet z zdravilom je vnesel vse zgoraj navedene spremembe, vendar je zaradi skladnosti povzetkov z glavnimi značilnostmi zdravila za vsa cepiva GSK prosil, če lahko še naprej predstavlja neželene učinke v obliki seznama in posebej navaja neželene učinke, o katerih so poročali v kliničnih preskušanjih, in neželene učinke, o katerih so poročali v obdobju trženja.
Priorix is indicated for the active immunisation against measles, mumps and rubella.
Cepivo Priorix je indicirano za aktivno imunizacijo proti ošpicam, mumpsu in rdečkam.
To be in line with current WHO recommendations the CHMP was of the opinion that delay in pregnancy should be changed from 3 months to 1 month after vaccination.
Zaradi skladnosti s trenutnim priporočilom SZO je CHMP menil, da je treba navodilo o izogibanju zanositvi spremeniti s 3 mesecev na 1 mesec po cepljenju.
Studies have shown that breast-feeding postpartum women vaccinated with live attenuated rubella vaccines may secrete the virus in breast milk and transmit it to breast-fed infants without evidence of any symptomatic disease.
Študije so pokazale, da se lahko pri poporodnih ženskah, ki dojijo, cepljenih z živim oslabljenim cepivom rdečk, virus izloča v materino mleko in prenese na dojenega otroka brez znakov simptomatske bolezni.
In the SmPC of Bulgaria, Cyprus, Estonia, Malta and the United Kingdom, it is stated that pregnancy must be avoided for one month after vaccination as compared to the three months in the SmPC of the countries involved in the MRP and other countries.
V povzetkih glavnih značilnosti zdravila za Bolgarijo, Ciper, Estonijo, Malto in Združeno kraljestvo je navedeno, da naj ženske ne zanosijo en mesec po cepljenju, medtem ko je v povzetkih glavnih značilnosti zdravila držav, ki so zdravilo odobrile v postopku z medsebojnim priznavanjem, in drugih državah, navedeno tri mesece.
The CHMP also noted that there are some published data at present that could justify the lifting of the absolute contraindication for pregnant women from MMR vaccines as it is believed that although the vaccination of pregnant women is not recommended, in some individual cases the benefit of vaccination of a pregnant woman might outweigh the risk.
CHMP je ugotovil tudi, da obstaja nekaj objavljenih podatkov, ki bi lahko upravičili odpravo absolutne kontraindikacije cepiv MMR pri nosečnicah, saj prevladuje mnenje, da so lahko koristi cepljenja za nosečnice v nekaterih premerih večje od tveganja, čeprav se cepljenje nosečnic ne priporoča.
The MAH proposed to use a general sentence and not to list the different vaccines.
Imetnik dovoljenja za promet z zdravilom je predlagal uporabo splošnega stavka brez navajanja različnih cepiv.
Also for clarity, the CHMP agreed to replace the company's proposal “In such cases, the risk-benefit of immunising with Priorix should be carefully evaluated” by “Patients with existing thrombocytopenia or a history of thrombocytopenia after measles, mumps or rubella vaccination should be immunized with caution”
Zaradi jasnosti se je CHMP strinjal, da se stavek, ki ga je predlagala družba, „V takih primerih je treba razmerje med tveganji in koristmi imunizacije s cepivom Priorix skrbno oceniti„ nadomesti z „Bolnike z obstoječo trombocitopenijo ali s trombocitopenijo po cepljenju proti ošpicam, mumpsu ali rdečkam v anamnezi je treba previdno imunizirati.“
However there is no evidence of transmission of these excreted vaccine viruses to susceptible contacts.
Vendar ni dokazov, da bi se virusa, ki se izločata iz cepiva, s stikom prenesla na dovzetne posameznike.
Accordingly to the SmPC guideline, the SmPC provides information on a particular medicinal product; therefore it should not include reference to other medicinal products.
V skladu s smernicami za povzetek glavnih značilnosti zdravila so v povzetku glavnih značilnosti zdravila informacije o določenih zdravilih, zato naj ne vključuje sklicev na druga zdravila.
Finally, the wording “adverse events” was replaced by “adverse reactions” in all the section as per the QRD comments.
B Izraz „neželeni dogodki“ je bil v vseh poglavjih v skladu z opombami QRD zamenjan z izrazom „neželeni učinki“ ..
The final agreed wording is: “Transmission of measles and mumps virus from vaccinees to susceptible contacts has never been documented.
Dogovorjeno je bilo naslednje končno besedilo: „Ni dokumentirano, da se virus ošpic in mumpsa s cepljenih posameznikov prenaša na dovzetne osebe.
However, since studies have not been conducted with Priorix in pregnant women the MAH proposed that pregnancy should be avoided 3 months after vaccination.
Vendar pa s cepivom Priorix pri nosečnicah niso izvedli nobenih študij, zato je imetnik dovoljenja za promet z zdravilom predlagal, da naj ženske ne zanosijo še 3 mesece po cepljenju.
Of the notified cases in 2010, almost 30% were hospitalized and a higher severity of the disease was observed in infants under one year of age and adults above 20 years, with respective proportions of hospitalised cases of 38% and 46%.Vaccination of children from 9 months onwards is therefore one tool to contain such outbreaks.
Od priglašenih primerov je bilo v letu 2010 skoraj 30 % hospitalizacij, pri čemer je bila pri dojenčkih, starih manj kot eno leto, in odraslih, starih več kot 20 let, oblika bolezni hujša, in sicer je bilo med prvimi hospitaliziranih 38 %, med drugimi pa 46 % bolnikov.
Published data from women of childbearing age that were vaccinated in the region of Central and South America demonstrate no or a negligible risk (0-0.2%) for CRS following vaccination of unknowingly pregnant women with a rubella containing vaccine.
Objavljeni podatki za ženske v rodni dobi, cepljene na območju srednje in južne Amerike, kažejo, da tveganja za KSR po cepljenju žensk, ki niso vedele, da so noseče, s cepivom, ki je vsebovalo virus rdečk, ni ali je zanemarljivo (0-0,2 %).
Mumps and rubella vaccine viruses have not been recognized to cause serious complications in HIV-infected persons, but as they are unlikely to benefit and complications could occur severely immunocompromised persons should not be vaccinated.
Ni bilo ugotovljeno, da bi virusi cepiv proti mumpsu in rdečkam povzročili hude zaplete pri bolnikih, okuženih z virusom HIV, vendar teh bolnikov ne cepimo, saj ni verjetno, da bi imeli od tega koristi, pri osebah s hudo oslabljenim imunskim sistemom pa bi se lahko pojavili tudi zapleti.
The MAH stated that there is insufficient experience in the use of Priorix in breastfeeding women and that vaccination of breastfeeding women can be considered if the benefit of vaccination outweighs the risk.
Imetnik dovoljenja za promet z zdravilom je navedel, da ni dovolj izkušenj z uporabo cepiva Priorix pri ženskah, ki dojijo, in da pri doječih ženskah pride cepljenje v poštev, če koristi cepljenja presegajo tveganja, ki so z njim povezana.
The MAH slightly modified the proposed text and the final wording agreed by the CHMP is: “Cases of worsening of thrombocytopenia and cases of recurrence of thrombocytopenia in subjects who suffered thrombocytopenia after the first dose have been reported following vaccination with live measles, mumps and rubella vaccines.
Imetnik dovoljenja za promet z zdravilom je nekoliko spremenil predlagano besedilo, tako da je končno besedilo sprejeto v soglasju z odborom CHMP: „Poročali so o primerih poslabšanja trombocitopenije in primerih ponovnega pojava trombocitopenije pri posameznikih, pri katerih se je trombocitopenija pojavila po prvem cepljenju s cepivom z živimi virusi ošpic, mumpsa in rdečk.
Because of this theoretical teratogenic risk, the WHO recommended in 2011 that rubella vaccination of pregnant women should be avoided in principle, and women who intend to become pregnant should be advised to delay for 1 month following rubella vaccination.
Zaradi tega teoretičnega teratogenega tveganja je SZO leta 2011 priporočila, da se nosečnice načeloma ne cepijo s cepivi proti rdečkam, ženskam, ki nameravajo zanositi, pa je treba svetovati, da še 1 mesec po cepljenju proti rdečkam ne zanosijo.
The paragraph on immunosuppression proposed by the MAH was considered outdated by the CHMP and a rewording was proposed.
CHMP meni, da je odstavek, ki ga je imetnik dovoljenja za promet z zdravilom predlagal o imunosupresiji, zastarel, zato je predlagal spremenjeno besedilo.
The CHMP noted that because of this theoretical teratogenic risk, the WHO recommended in 2011 that rubella vaccination of pregnant women should be avoided in principle, and women who intend to become pregnant should be advised to delay for 1 month following rubella vaccination.
CHMP je ugotovil, da je zaradi tega teoretičnega teratogenega tveganja SZO leta 2011 priporočila, da se nosečnic načeloma ne sme cepiti s cepivi virusa rdečk, ženskam, ki nameravajo zanositi, pa je treba svetovati, da še 1 mesec po cepljenju proti rdečkam ne zanosijo.
Therefore a second dose given preferable 3 months after the first dose is mandatory in this age group to ensure appropriate protection against measles, mumps and rubella.
Zato je treba za zagotovitev ustrezne zaščite pred ošpicami, mumpsom in rdečkami v tej starostni skupini obvezno uporabiti še drugi odmerek, najbolje 3 mesece po prvem odmerku.
delete wording about age of vaccination (covered in section 4.2) The Company also suggested rephrasing the paragraph about the idiopathic thrombocytopenic purpura (ITP).
Družba je predlagala tudi preoblikovanje besedila odstavka o idiopatični trombocitopenični purpuri (ITP).
In addition the MAH proposed to delete the wording about comparative studies that demonstrated a statistically significant lower incidence of pain, redness and swelling at the injection site with Priorix compared to the reference product (Ipp et al., 2004; Ipp et al., 2006; Knutsson et al., 2006; Taddio et al., 2009; Wellington and Goa, 2003).
Zaradi skladnosti s smernicami za povzetek glavnih značilnosti zdravila je imetnik dovoljenja za promet z zdravilom predlagal seznam neželenih učinkov v skladu z razvrstitvijo po organskih sistemih MedDRA. Imetnik dovoljenja za promet z zdravilom je predlagal tudi črtanje besedila o primerjalnih študijah, ki so dokazale značilno nižjo pojavnost bolečine, rdečine in otekline na mestu injiciranja s cepivom Priorix v primerjavi z referenčnim zdravilom (Ipp et al., 2004; Ipp et al., 2006; Knutsson et al., 2006; Taddio et al., 2009; Wellington and Goa, 2003).
An association between lack of measles-specific antibodies after vaccination and low CD+ T-lymphocyte counts (<600cells/mm3) was reported in published studies (Moss et al. 2003).
V objavljenih študijah (Moss et al. 2003) poročajo o povezavi med pomanjkanjem protiteles proti ošpicam po cepljenju in majhnim številom celic CD+ T-limfocitov (< 600 celic/mm3).